Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis

Osteoarthritis and Cartilage

Volumn 12, Issue 4, 2004, Pages 263-268

  Abadie, Eric ^a   Ethgen, Dominique ^b   Avouac, Bernard ^c   Bouvenot, Gilles ^d   Branco, Jaime ^e   Bruyere, Olivier ^f   Calvo, Gonzalo ^g   Devogelaer, Jean Pierre ^h   Dreiser, Renee Lilianee ⁱ   Herrero Beaumont, Gabriel ⁱ   Kahan, Andre ^j   Kreutz, Godfried ^k   Laslop, Andrea ^l   Lemmel, Ernst Martin ^m   Nuki, George ⁿ   Van De Putte, Leo ^o   Vanhaelst, Luc ^p   Reginster, Jean Yves ^f  

^a AFSSAPS   (France)

^b GLAXOSMITHKLINE   (United States)

^c HENRI MONDOR HOSPITAL   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HOSPITAL EGAS MONIZ   (Portugal)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ Department of Rheumatology ^*  (Spain)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k ARM   (Germany)

^l INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^m Max Grundig Clinic   (Germany)

ⁿ WESTERN GENERAL HOSPITAL   (United Kingdom)

^o RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^p UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

Biochemical markers; Drugs; Osteoarthritis; Registration; Studies; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; DIACEREIN; GLUCOSAMINE SULFATE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; BONE RADIOGRAPHY; CARTILAGE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; HUMAN; JOINT FUNCTION; JOINT PROSTHESIS; MEDICAL DOCUMENTATION; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL TECHNOLOGY; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATIENT ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOLOGICAL PROCEDURES; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDATION PROCESS; X RAY;

EID: 11144357578     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2004.01.006     Document Type: Article

References (35)

1. Reginster JY. The prevalence and burden of osteoarthritis. Rheumatology 2002;41:3-6.
2. Prevalence of self-reported arthritis or chronic joint symptoms among adults. MMWR 2002;51:948-950.
3. Guidance for the industry. Clinical development programs for drugs, devices and biologicals products intended for the treatment of osteoarthritis. US Department of Health and human Services. Food and Drug Administration, Center for Drug Evaluation and Research. July 1999. Available from: Ttp://www.fda. gov/cder/guidance/2199dft.htm
4. Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. July 1998. Available from: Http://www. emea.eu.int/pdfs/human/ewp/078497en.pdf
5. Group for the Respect of Ethics and Excellence in Sciences (GREES). Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis 1996;55:552-7.
6. Peterfy CG. Imaging the disease process. Curr Opin Rheumatol 2002;14:590-6.
7. Garnero P. Osteoarthritis: Biological markers for the future. Joint Bone Spine 2002;69:525-30.
8. Reginster JY, Bruyere O, Henrottin Y. New perspectives in the management of ostearthritis structure modification: Facts or fantasy? J Rheumatol 2003;30: 14-20.
9. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. and the Diacerein Study Group. Efficacy and safety of diacerein in osteoarthritis of the knee. Arthritis Rheum 2000;43:2339-48.
10. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. for the ECHODIAH Investigator Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis. Arthritis Rheum 2001;4:2539-47.
11. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effect of glucosamine sulfate on osteoarthritis progresion: A randomized placebo-controlled clinical trial. Lancet 2001;27: 251-65.
12. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulphate delays progression of knee osteoarthritis: A 3-year, randomized placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-23.
13. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrottin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. A comprehensive meta-analysis. Arch Intern Med. 2003;163:1514-22.
14. Brandt KD, Mazucca SA, Conrozier T, Dacre JE, Peterfy CG, Provvedini D, et al. What is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with osteoarthritis. J Rheumatol 2002;29:1308-20.
15. Mazucca SA, Brandt KD, Buckwalter KA. Detection of radiographic joint space narrowing in subjects with knee ostearthritis. Arthritis Rheum 2003;48:385-90.
16. Gale DR, Chaisson CE, Totterman SM, Schwartz RK, Gale ME, Felson D. Meniscal subluxation: Association with osteoarthritis and joint space narrowing. Osteoarthritis and Cart 1999;7:526-32.
17. Conrozier T, Lequesne M, Favret H, Taccoen A, Mazieres B, Dougados M, et al. Measurement of the radiological hip joint space width. An evaluation of various methods of measurement. Osteoarthritis and Cart 2001;9:281-6.
18. Gordon C, Wu C, Petrefy CG, Li J, Duryea J, Klifa C, Genant HK. Automated measurement of radiographic hip joint space width. Med Phys 2001;28: 267-77.
19. Biswal S, Hastie T, Andriacchi TP, Bergman GA, Dillingham MF, Lang P. Risk factor for progressive cartilage loss in the knee. Arthritis Rheum 2002; 46:2884-92.
20. Cicuttini FM, Wluka AE, Forbes A, Wolfe R. Comparison of tibial cartilage volume and radiologic grade of the tibiofemoral joint. Arthritis Rheum 2003;48:682-8.
21. Pessis E, Drape JL, Ravaud P, Chevrot A, Dougados M, Ayral X. Assessment of progression in knee osteoarthritis: Results of a 1 year study comparing arthroscopy and MRI. Osteoarthritis Cart 2003;11: 361-9.
22. Raynaud JP, Kauffman C, Beaudoins G, Berthaumie MJ, de Guise JA, Bloch DA, et al. Reliability of quantification imaging system using magnetic resonance images to measure cartilage thickness and volume in human normal and osteoarthritic knees. Osteoarthritis and Cart 2003;11:351-60.
23. Gandy SJ, Dieppe PA, Keen MC, Maciewic RA, Watt I, Waterton JC. No loss of cartilage volume over three years in patients with knee osteoarthritis as assessed by MRI. Osteoarthritis and Cart 2002;10:929-37.
24. Link TM, Steinbach LS, Ghosh P, Ries M, Lu Y, Majumdar S. Osteoarthritis: MRI imaging findings in different stages of disease and correlation with clinical findings. Radiology 2003;226:373-81.
25. Mosher TJ, Dardzinski BJ, Smith MB. Human articular cartilage: Influence of aging and early symptomatic degeneration on the spatial variation of T2 Radiology 2000;214:259-66.
26. Liess C, Lussert S, Karger N, Heller M, Gluer CC. Detection of changes in cartilage water content using MRI T2 mapping in vivo. Osteoarthritis and Cart 2002;10:907-13.
27. Nieminen MT, Rieppo J, Toyras J, Hakumaki M, Silvennoinen J, Hyttinen MM, et al. T2 relaxation reveals spatial collagen architecture in articular cartilage: A comparative quantitative MRI and polarized light microscopic study. Magn Reson Med 2001; 46:487-93.
28. Bashir A, Gray ML, Harke J, Burstein D. Nondestructive imaging of human cartilage glycosaminoglycan concentration by MRI. Magn Reson Med 1999;41: 857-65.
29. Tiderius CJ, Olson LE, Leander P, Ekberg O, Dahlberg L. Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) in early knee osteoarthritis. Magn Reson Med 2003;49:488-92.
30. Regatte RR, Akella SV, Borthakur R, Reddy R. Proton spin-lock ratio imaging for quantification of glycosaminoglycans in articular cartilage. J Magn Reson Imaging 2003;17:114-21.
31. Young-Min SA, Cawston TE. Markers of joint destruction: principles, problems and potential. Ann Rheum Dis 2001;60:545-8.
32. Poole R. Can serum biomarkers assays measure the progression of cartilagedegeneration in osteoarthritis. Arthritis Rheum 2002;46:2549-52.
33. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-24.
34. Bruyere O, Collette J, Ethgen O, Rovati LC, Giacovelli G, Henrottin Y, et al. Biochemical markers of bone and cartilage remodeling in prediction of long term progression of knee osteoarthritis, J Rheumatol 2003;30:1043-50.
35. Pham T, Van Der Heidje D, Lasserre M, Altman RD, Anderson JJ, Bellamy N, et al. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648-54.